Plain-English translation of NCT07571551 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a combination of two medications called and given before and after surgery for clear cell kidney cancer. Researchers want to see if starting this treatment before surgery can help shrink tumors and improve outcomes, compared to standard approaches. The study includes patients with different stages of kidney cancer, from localized to advanced disease.
Doctors have found that combining an immune-boosting drug with a targeted therapy works well for advanced kidney cancer, but it's newer to use this combination *before* surgery to try to make tumors smaller. This trial aims to understand whether the medication can help more patients by starting earlier, potentially making surgery easier and improving long-term survival.
You likely qualify if…
You likely don't qualify if…
You would receive four 3-week cycles of the two medications before surgery—an intravenous infusion once every three weeks and a daily oral pill. About 7 to 10 days after your last dose, you would have surgery to remove part or all of your kidney. After surgery, depending on your results, you would continue receiving the medication (either one or both drugs) for up to 17 more cycles as follow-up treatment. Throughout, you'll have regular clinic visits, blood tests, and imaging scans to monitor how well the treatment is working and manage any side effects.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
China